Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2009 Dec 9;27(52):7299-303. doi: 10.1016/j.vaccine.2009.08.023. Epub 2009 Aug 25.

The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali.

Author information

  • 1Malaria Research and Training Center, Faculty of Medicine, Pharmacy and Odonto-Stomatology, Department of Epidemiology of Parasitic Diseases-BP 1805 Bamako, Mali. Bouba.traore@mrtcbko.org

Abstract

Antibodies play a key role in controlling blood stage malaria infections, and an effective blood stage malaria vaccine will likely require that it induce vaccine-specific memory B cells (MBCs). Our previous studies showed that the addition of the TLR9 agonist CpG to Plasmodium falciparum protein subunit vaccines greatly increased their efficacy in inducing MBCs in nonimmune U.S. volunteers. Here we show that in contrast the same CpG-containing malaria vaccine did not enhance the acquisition of MBCs in semi-immune adults living in Mali. Understanding the molecular basis of this apparent refractoriness to TLR9 agonist will be of significant interest in vaccine design.

PMID:
19712767
[PubMed - indexed for MEDLINE]
PMCID:
PMC2788035
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk